Below are the most recent publications written about "Mucin-1" by people in Profiles.
-
Kawano T, Englisch C, Hisada Y, Paul D, Archibald S, Grover S, Pabinger I, Ay C, Mackman N. Mucin 1 and venous thrombosis in tumor-bearing mice and patients with cancer. Thromb Res. 2024 05; 237:23-30.
-
Wu D, Chapela PJ, Barrows CML, Harrington DA, Carson DD, Witt RL, Mohyuddin NG, Pradhan-Bhatt S, Farach-Carson MC. MUC1 and Polarity Markers INADL and SCRIB Identify Salivary Ductal Cells. J Dent Res. 2022 07; 101(8):983-991.
-
Gono T, Masui K, Nishina N, Kawaguchi Y, Kawakami A, Ikeda K, Kirino Y, Sugiyama Y, Tanino Y, Nunokawa T, Kaneko Y, Sato S, Asakawa K, Ukichi T, Kaieda S, Naniwa T, Okano Y, Kuwana M. Risk Prediction Modeling Based on a Combination of Initial Serum Biomarker Levels in Polymyositis/Dermatomyositis-Associated Interstitial Lung Disease. Arthritis Rheumatol. 2021 04; 73(4):677-686.
-
Forder J, Smith M, Wagner M, Schaefer RJ, Gorky J, van Golen KL, Nohe A, Dhurjati P. A Physiologically-Based Pharmacokinetic Model for Targeting Calcitriol-Conjugated Quantum Dots to Inflammatory Breast Cancer Cells. Clin Transl Sci. 2019 11; 12(6):617-624.
-
Khalili M, Zhou H, Thadi A, Daniels L, Fan Z, Morano WF, Ang J, Goldstein E, Polyak B, Mapow BC, Cheng H, Bowne WB. Slippery Nanoparticles as a Diffusion Platform for Mucin Producing Gastrointestinal Tumors. Ann Surg Oncol. 2020 Jan; 27(1):76-84.
-
Perepelyuk M, Sacko K, Thangavel K, Shoyele SA. Evaluation of MUC1-Aptamer Functionalized Hybrid Nanoparticles for Targeted Delivery of miRNA-29b to Nonsmall Cell Lung Cancer. Mol Pharm. 2018 03 05; 15(3):985-993.
-
Kato K, Zemskova MA, Hanss AD, Kim MM, Summer R, Kim KC. Muc1 deficiency exacerbates pulmonary fibrosis in a mouse model of silicosis. Biochem Biophys Res Commun. 2017 11 25; 493(3):1230-1235.
-
Eminaga O, Wei W, Hawley SJ, Auman H, Newcomb LF, Simko J, Hurtado-Coll A, Troyer DA, Carroll PR, Gleave ME, Lin DW, Nelson PS, Thompson IM, True LD, McKenney JK, Feng Z, Fazli L, Brooks JD. MUC1 Expression by Immunohistochemistry Is Associated with Adverse Pathologic Features in Prostate Cancer: A Multi-Institutional Study. PLoS One. 2016; 11(11):e0165236.
-
Perepelyuk M, Maher C, Lakshmikuttyamma A, Shoyele SA. Aptamer-hybrid nanoparticle bioconjugate efficiently delivers miRNA-29b to non-small-cell lung cancer cells and inhibits growth by downregulating essential oncoproteins. Int J Nanomedicine. 2016; 11:3533-44.
-
Lee KM, Nam K, Oh S, Lim J, Kim YP, Lee JW, Yu JH, Ahn SH, Kim SB, Noh DY, Lee T, Shin I. Extracellular matrix protein 1 regulates cell proliferation and trastuzumab resistance through activation of epidermal growth factor signaling. Breast Cancer Res. 2014 Dec 11; 16(6):479.